サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：呼吸器治療薬およびデバイスの世界市場：2022-2028年
市場調査レポート
商品コード
1123059

呼吸器治療薬およびデバイスの世界市場：2022-2028年

Global Respiratory Drugs and Devices Market Research and Forecast, 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 250 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
呼吸器治療薬およびデバイスの世界市場：2022-2028年
出版日: 2022年07月14日
発行: Orion Market Research
ページ情報: 英文 250 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の呼吸器治療薬およびデバイスの市場規模は予測期間中に7.2％のCAGRで成長すると予測されています。

ライフスタイルの変化と肥満率の増加が同市場を牽引すると考えられています。また、喫煙率の高さ、都市化の進展、汚染度の上昇も市場の成長に大きく寄与する要因であると推定されます。一方で、新興国における償還の不足や限定的な認知度、低いアベイラビリティなどが市場の成長を妨げる主な要因となっています。

当レポートでは、世界の呼吸器治療薬およびデバイスの市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 レポートの概要

第2章 市場概要・洞察

第3章 競合情勢

  • 主要企業分析
  • 主要戦略分析
  • COVID-19が主要企業に与える影響

第4章 市場決定要因

  • 推進要因
  • 抑制要因
  • 機会

第5章 市場分析：区分別

  • 世界の呼吸器治療薬およびデバイス市場：製品別
    • 治療機器
    • 診断およびモニタリング用機器
    • 消耗品および付属品
  • 世界の呼吸器治療薬およびデバイス市場：薬剤別
    • 呼吸器治療薬：投与経路別
    • 呼吸器治療薬：薬剤クラス別
  • 世界の呼吸器治療薬およびデバイス市場：エンドユーザー別
    • 病院
    • 在宅ケア
    • その他

第6章 地域分析

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第7章 企業プロファイル

  • Astrazeneca
  • Adamis（Admp）
  • Ads Biotechnology
  • Air Liquide
  • Alung Technologies
  • Alvogen
  • Anaxsys
  • Applied Biocode Inc.
  • Avita Medical
  • Bayer AG
図表

LIST OF TABLES

  • 1. GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET BY PRODUCT, 2020-2027 ($ MILLION)
  • 3. GLOBAL RESPIRATORY THERAPEUTIC DEVICES MARKET BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL RESPIRATORY DIAGNOSTIC AND MONITORING DEVICES MARKET BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL RESPIRATORY CONSUMABLES AND ACCESSORIES METERS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET BY RESPIRATORY DRUGS, 2020-2027 ($ MILLION)
  • 7. GLOBAL RESPIRATORY DRUGS BY ROUTE OF ADMINISTRATION MARKET BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL RESPIRATORY DRUGS BY DRUG CLASS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET BY END-USERS, 2020-2027 ($ MILLION)
  • 10. GLOBAL HOSPITALS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL HOME CARE MARKET BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL OTHER END-USERS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 14. NORTH AMERICAN RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 15. NORTH AMERICAN RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2020-2027 ($ MILLION)
  • 16. NORTH AMERICAN RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY RESPIRATORY DRUGS, 2020-2027 ($ MILLION)
  • 17. NORTH AMERICAN RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
  • 18. EUROPEAN RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 19. EUROPEAN RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2020-2027 ($ MILLION)
  • 20. EUROPEAN RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY RESPIRATORY DRUGS, 2020-2027 ($ MILLION)
  • 21. EUROPEAN RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
  • 22. ASIA-PACIFIC RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 23. ASIA-PACIFIC RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2020-2027 ($ MILLION)
  • 24. ASIA-PACIFIC RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY RESPIRATORY DRUGS, 2020-2027 ($ MILLION)
  • 25. ASIA-PACIFIC RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
  • 26. REST OF THE WORLD RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2020-2027 ($ MILLION)
  • 27. REST OF THE WORLD RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY RESPIRATORY DRUGS, 2020-2027 ($ MILLION)
  • 28. REST OF THE WORLD RESPIRATORY DRUGS AND DEVICES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET SHARE BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET, 2021-2027 (%)
  • 4. GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET SHARE BY PRODUCT, 2020 VS 2027 (%)
  • 5. GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET SHARE BY RESPIRATORY DRUGS, 2020 VS 2027 (%)
  • 6. GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET SHARE BY END-USERS, 2020 VS 2027 (%)
  • 7. GLOBAL RESPIRATORY DRUGS AND DEVICES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL RESPIRATORY THERAPEUTIC DEVICES MARKET BY REGION, 2020 VS 2027 (%)
  • 9. GLOBAL RESPIRATORY DIAGNOSTIC AND MONITORING DEVICES MARKET BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL RESPIRATORY CONSUMABLES AND ACCESSORIES METERS MARKET BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL RESPIRATORY DRUGS BY ROUTE OF ADMINISTRATION MARKET BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL RESPIRATORY DRUGS BY DRUG CLASS MARKET BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL HOSPITALS MARKET BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL HOME CARE MARKET BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL OTHER END-USERS MARKET BY REGION, 2020 VS 2027 (%)
  • 16. US RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
  • 17. CANADA RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
  • 18. UK RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
  • 19. FRANCE RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
  • 20. GERMANY RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
  • 21. ITALY RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. SPAIN RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. REST OF EUROPE RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. INDIA RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. CHINA RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. JAPAN RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. SOUTH KOREA RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. REST OF THE WORLD RESPIRATORY DRUGS AND DEVICES MARKET SIZE, 2020-2027 ($ MILLION)
目次
Product Code: MD-1203

Global Respiratory Drugs and Devices Market Research By Product (Respiratory Therapeutic Devices, Respiratory Diagnostic and Monitoring Devices, and Respiratory Consumables and Accessories Meters), By Respiratory Drugs (Respiratory Drugs by Route of Administration and Respiratory Drugs by Drug Class), and By End-Users (Hospitals, Home Care and Other End-Users) Forecast 2021-2027

The global respiratory drugs and devices market is growing at a CAGR of 7.2% during the forecast period. Changing lifestyle and the growing rate of obesity is considered as the prime factors affecting and driving the market. Additionally, the high frequency of people smoking, increase in urbanization along with the rising level of pollution, are also estimated to be the major factors that are contributing significantly towards the growth of the market. However, the unfavorable scenarios in reimbursement and limited awareness and availability in emerging markets are the major factors constraints that are hindering the growth of the global respiratory drugs and devices market across the globe.

Moreover, the growing demand for remote monitoring and home care products are the key factors that are creating opportunities in the market. New product launches and collaboration in the market are likely to drive the growth of the global respiratory drugs and devices. For instance, in July 2020, Novartis AG had put forward the results from the second phase IRIDIUM study. This study result indicates that one daily treatment dose which is high and medium of enerzair; breezhaler had highlighted the improvement in the functionality of lung along with asthma.

Impact of COVID-19 on the Global Respiratory Drugs and Devices Market

The global respiratory drug and device market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted manufacturing and transportation activities. However, with the lockdown restriction lifted it is likely to increase the output for respiratory drug devices for supporting the patients.

Segmental Outlook

The market is segmented based on product, respiratory drugs, and end-users. By product, the market is segmented into respiratory therapeutic devices, respiratory diagnostic and monitoring devices, respiratory consumables, and accessories meters. Further, the respiratory drug is segmented into respiratory drugs by route of administration and respiratory drugs by drug class. Based on end-users hospitals, home care, and other end-users.

Global Respiratory Drugs and Devices Market by Respiratory, 2020 (%)

Global Respiratory Drugs and Devices Market by Respiratory

Based on the product, respiratory therapeutic devices hold a significant share in the market. These devices are owing to be utilized in order to improve pulmonary function, enhance lung oxygenation, along with providing support for the removal of mucus from the bronchi during respiratory therapy. Additionally, the rising pervasiveness of smoking and growing susceptibility to accidents and airborne infections that cause various injuries such as chest and nasal which can lead to respiratory problems is also supporting in increasing the demand for therapeutic respiratory devices.

Regional Outlooks

Global respiratory drugs and devices market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is divided into North America, Europe, Asia Pacific, and Rest of the World. North America is estimated to be the leading region in the global respiratory drugs and devices market. Increasing in respiratory diseases and disorders is also one of the major factors driving the growth of the market in the region. Additionally, leading manufactures and players are present in the region along with technological advancement that are some other factors that are promoting the growth of the market.

Global Respiratory Drugs and Devices Market Growth, by Region 2021-2027

Global Respiratory Drugs and Devices Market Growth, by Region

Asia-Pacific will have Considerable Growth in the Global Respiratory Drugs and Devices Market

The Asia-Pacific region is regarded as the economies to grow and is expected to create an opportunity for market of global respiratory drugs and devices market. The rising incidence of chronic respiratory diseases such as asthma and COPD is also one of the major factors for the growth of the market in the Asia-Pacific region. Further, the market is driven by increasing urbanization along with pollution levels is another factor that is supporting the growth of the market in the region.

Market Players Outlook

Key companies in the global respiratory drugs and devices market include AstraZeneca, Bayer AG, Ge Healthcare Ltd., GlaxoSmithKline, and Novartis AG among others. To survive in the market, these players adopt different marketing strategies such as product launches and mergers and acquisitions. For instance, in November 2021, ALung Technologies had received the approval from FDA for its Hemolung respiratory support platform. This platform is designed in such a manner that in order to provides low-flow extracorporeal carbon dioxide removal (ECCO2R) for patients with acute respiratory failure.

In June 2021, Teva Pharmaceuticals had introduced the first generic version of twice-daily PERFOROMIST, formoterol fumarate inhalation solution, 20 mcg/2 ML, in the US for the purpose of providing treatment to patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

In November 2020, Philips had introduced a non-invasive ventilator that is BiPAP A40 in order to remotely monitor patients suffering from a chronic obstructive pulmonary disease (COPD) along with support them to breathe conveniently.

In September 2020, Boehringer Ingelheim International GmbH announced the launch of the first FDA-approved inhalant therapy that is Aservo Equihaler for horses suffering from equine asthma.

In September 2020, Invacare Corp., one of the leading manufacturers and distributors of medical equipment had introduced a new oxygen concentrator in order to address the rising global demand for respiratory equipment.

The Report Covers

Market value data analysis of 2021 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global respiratory drugs and devices market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Respiratory Drugs and Devices Industry
  • Recovery Scenario of Global Respiratory Drugs and Devices Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Respiratory Drugs and Devices by Product
    • 5.1.1. Respiratory Therapeutic Devices
    • 5.1.2. Respiratory Diagnostic and Monitoring Devices
    • 5.1.3. Respiratory Consumables and Accessories Meters
  • 5.2. Respiratory Drugs and Devices by Respiratory Drugs
    • 5.2.1. Respiratory Drugs by Route of Administration
    • 5.2.2. Respiratory Drugs by Drug Class
  • 5.3. Respiratory Drugs and Devices by End-Users
    • 5.3.1. Hospitals
    • 5.3.2. Home Care
    • 5.3.3. Other End-Users

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Astrazeneca
  • 7.2. Adamis (Admp)
  • 7.3. Ads Biotechnology
  • 7.4. Air Liquide
  • 7.5. Alung Technologies
  • 7.6. Alvogen
  • 7.7. Anaxsys
  • 7.8. Applied Biocode Inc.
  • 7.9. Avita Medical
  • 7.10. Bayer AG **List not exhaustive